End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.78 CNY | +0.52% | -7.05% | -23.95% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.95% | 258M | - | ||
+5.09% | 106B | A- | ||
-3.11% | 63.67B | A- | ||
+74.29% | 49.32B | B | ||
+15.53% | 38.56B | B | ||
+5.13% | 32.65B | A- | ||
+10.99% | 20.08B | B- | ||
+13.07% | 17.01B | C+ | ||
+18.38% | 15.41B | B- | ||
+4.83% | 14.41B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300839 Stock
- Ratings Ningbo Bohui Chemical Technology Co.,Ltd